This advert is not available!
Lund University was founded in 1666 and is repeatedly ranked among the world’s top universities. The University has around 47 000 students and more than 8 800 staff based in Lund, Helsingborg and Malmö. We are united in our efforts to understand, explain and improve our world and the human condition.
Lund University welcomes applicants with diverse backgrounds and experiences. We regard gender equality and diversity as a strength and an asset.
The research group
The Chemical Biology & Therapeutics is a multidisciplinary team at Lund University and University of Gothenburg that explore new therapeutic strategies using organic/medicinal chemistry, in-vivo/in-vitro biology, and applied physics. The lab was recently awarded funding for studying in-vivo assembled therapeutics and for an Electronic Neuropharma project (e-NeuroPharma), aiming to address CNS disorders by self-assembled therapeutics. In the e-Neuropharma effort, we will develop self-organizing molecular systems that exert both pharmaceutical activity and electrical functionality to explore new therapeutics for neurodegenerative diseases. The latter is a collaboration with the organic bioelectronic team at Linköping University, Karolinska Institute and Chalmers University of Thechnology.
Work Tasks
Administration and evaluation of in-vivo assembled conductive polymers from a materials science view. Among the tasks is to micro- and nanoinject polymers to living organisms and to characterize these with different microscopy techniques (electron-, optical-, and x-ray microscopy) both post mortem and in vivo.
Qualifications
Requirements
Desirable qualifications
Type of employment | Temporary position |
---|---|
Contract type | Full time |
First day of employment | Enligt överenskommelse |
Salary | Månadslön |
Number of positions | 1 |
Full-time equivalent | 100 % |
City | Lund |
County | Skåne län |
Country | Sweden |
Reference number | PA2020/682 |
Contact |
|
Union representative |
|
Published | 03.Mar.2020 |
Last application date | 20.Mar.2020 11:59 PM CET |